首页 › 期刊 › 医学 › JTO Clinical and Research Reports
JTO Clinical and Research Reports
出版商:Elsevier · ISSN:2666-3643 · 国家/地区:US · 类型:journal · OA 开放获取 · 官网:https://www.journals.elsevier.com/jto-clinical-and-research-...
研究主题:Lung Cancer Treatments and Mutations · Lung Cancer Research Studies · Lung Cancer Diagnosis and Treatment · Cancer Immunotherapy and Biomarkers · Cancer Genomics and Diagnostics
数据覆盖:10 个公开学术数据源交叉核验(crossref、doaj、fqb、jcr、openalex、scimago、submission、wikidata、xr、cwts)。
数据来源与实体核验
期刊官网 · OpenAlex 期刊实体 · Wikidata 期刊实体
核心指标
- 影响因子(JCR 2025):3.600
- JCR 分区:Q2(ONCOLOGY)
- 中科院分区(2025):医学 4区,大类排名 2709/5603;小类:ONCOLOGY 肿瘤学 4区,排名 195/318
- 新锐分区(2026):医学 2区
- SJR:1.708(Q1),2025 年,United States
- CWTS 2025:SNIP 1.134 · IPP 3.726 · 自引率 2.3%
- h-index:33
- i10 指数:203
- 近两年篇均被引:1.71
- 载文量 880 · 总被引 6296
- Crossref DOI 总量:879,近期 388
逐年趋势
- 近年影响因子:2023 3 → 2024 3.5
- 近年 SJR:2021 0.674(Q2) → 2022 0.923(Q2) → 2023 1.32(Q1) → 2024 1.53(Q1) → 2025 1.71(Q1)
投稿参考
- DOAJ 收录的开放获取期刊,收取文章处理费(APC)
- 版面费(APC)约 $2000 USD(以期刊官网为准)
- 提供 LaTeX 投稿模板(elsarticle.cls)
同学科期刊推荐
- CA-A CANCER JOURNAL FOR CLINICIANS — IF 685.2 · JCR Q1 · 中科院1区(Top)
- The Lancet — IF 109.0 · JCR Q1 · 中科院1区(Top)
- MMWR Surveillance Summaries — IF 96.9 · JCR Q1 · 中科院1区(Top)
- Nature Reviews Clinical Oncology — IF 94.6 · JCR Q1 · 中科院1区(Top)
- Nature Reviews Drug Discovery — IF 91.2 · JCR Q1 · 中科院1区(Top)
- New England Journal of Medicine — IF 84.5 · JCR Q1 · 中科院1区(Top)
- Signal Transduction and Targeted Therapy — IF 81.2 · JCR Q1 · 中科院1区(Top)
- Annals of Oncology — IF 80.4 · JCR Q1 · 中科院1区(Top)
常见问题
《JTO Clinical and Research Reports》的影响因子是多少?
根据 JCR 2025 年数据,《JTO Clinical and Research Reports》的最新影响因子(IF)为 3.600。
《JTO Clinical and Research Reports》是几区期刊?
《JTO Clinical and Research Reports》中科院分区(2025年版)为医学4区,JCR 分区为 Q2。
《JTO Clinical and Research Reports》是开放获取(OA)期刊吗?
是,《JTO Clinical and Research Reports》是开放获取(Open Access)期刊,已被 DOAJ 收录,发表需支付文章处理费(APC)。
《JTO Clinical and Research Reports》的版面费(APC)是多少?
根据 OpenAlex 收录的价目,《JTO Clinical and Research Reports》的文章处理费(APC)约为 $2000 美元。实际费用与豁免政策请以期刊官网为准。
本刊近期代表论文
- Lung Adenocarcinoma Developing Pleomorphic Carcinoma With ERBB3 Amplification After Acquired Resistance to Sotorasib: A Case Report (2026 · 被引 1)
- Pembrolizumab Plus Chemotherapy for Metastatic Squamous Non‒Small-Cell Lung Cancer: Long-Term Follow-Up of the KEYNOTE-407 China Study (2026)
- Efficacy of Adding Immune Checkpoint Inhibition to Chemotherapy, With or Without VEGF Inhibition, in Patients With Advanced EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis With Reconstructed Individual Patient Data (2026)
- Clinical Activity of RET TKI Plus Chemotherapy After Progression on a RET TKI in a RET Fusion–Positive NSCLC Real-World Cohort: A Brief Report (2026)
- Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (2025 · 被引 6)
- Brief Report: Multi-Institution Real-World Analysis Evaluating Safety, Efficacy, and ctDNA Dynamics After Tarlatamab in Patients With Previously Treated SCLC and LCNEC (2025 · 被引 3)